Dr. Fakhri on Daratumumab Plus VMP in Multiple Myeloma

Video

In Partnership With:

Bita Fakhri, MD, MPH, a professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the data behind the frontline approval of daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) in multiple myeloma.

Bita Fakhri, MD, MPH, a professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the data behind the frontline approval of daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) in multiple myeloma.

In May 2018, the FDA approved daratumumab plus VMP for the treatment of patients with newly diagnosed disease who are ineligible for stem cell transplant. The decision was based on phase III findings from the ALCYONE study. The study had outstanding results, Fakhri says, meeting all its efficacy endpoints. The progression free survival at about 16 months was significantly better in the daratumumab with VMP group compared with VMP alone. The objective response rate was also much higher, notes Fakhri.

VMP is a primarily European regimen that is not often utilized by American physicians, states Fakhri. However, the approval dispels the notion that elderly and frail patients cannot tolerate combination therapy. Not only did these patients benefit in the trial, but they were able to tolerate it very well. The toxicity profiles were similar compared with the younger population, adds Fakhri.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD